Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Pan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
“The clinical successes with current epigenetic drugs have led to a big increase in interest from the pharmaceutical industry in developing compounds that will target epigenetic abnormalities in cancers (Kelly et al. 2010; Dawson et al. 2011; Arrowsmith et al. 2012).”
BackgroundSmall molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Histone Modifications and Cancer
Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,024
“…tools that can be used are the recently described selective, cell-active inhibitors of EZH2, DOT1L, SMYD2, G9a/GLP1, PRMT3, JMJD3, LSD1, BET (BRD2-4), L3MBTL1, L3MBTL3, CBP/EP300, PCAF, and BAZ bromodomains (Arrowsmith et al. 2012; Muller and Brown 2012; James et al. 2013; Gallenkamp et al. 2014).”
BackgroundMicrobial Regulation of Host Physiology by Short-chain Fatty Acids
van der Hee, B., & Wells, J. M. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.02.001 · Cited by 980
Geddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
The world of protein acetylation
Drazic, A., Myklebust, L. M., Ree, R., & Arnesen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.06.007 · Cited by 804
“So far, 17–22 ‘classical’ KATs have been identified in the human genome [14,15,167,186].”
BackgroundA Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics
Mutua, V., & Gershwin, L. J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08804-7 · Cited by 639
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 576
Highly evolvable malaria vectors: The genomes of 16 Anopheles mosquitoes
Neafsey, D. E., Waterhouse, R. M., Abai, M. R., Aganezov, S. S., Alekseyev, M. A., Allen, J. E., Amon, J., Arcà, B., Arensburger, P., Artemov, G., et al. (2015) · Science · doi:10.1126/science.1258522 · Cited by 578
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Targeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Hai, Y., & Christianson, D. W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2134 · Cited by 521
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485
Non-histone protein methylation as a regulator of cellular signalling and function
Biggar, K. K., & Li, S. S.-C. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3915 · Cited by 479
Histone lysine demethylases as targets for anticancer therapy
Højfeldt, J. W., Agger, K., & Helin, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4154 · Cited by 455
The landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Konze, K. D., Ma, A., Li, F., Barsyte-Lovejoy, D., Parton, T., MacNevin, C. J., Liu, F., Gao, C., Huang, X.-P., Kuznetsova, E., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400133j · Cited by 452
“The docking model of UNC1999 suggests that: (1) the secondary amide and pyridone maintain the respective key hydrogen bonds with Asn688 and His689, (2) the indazole is buried in a hydrophobic pocket, and (3) the N-isopropyl piperazine does not interact with the protein (Figure 1C – D).”
BackgroundSelf-citationBromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Struck, A., Thompson, M. L., Wong, L. S., & Micklefield, J. (2012) · ChemBioChem · doi:10.1002/cbic.201200556 · Cited by 430
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
“KDMs can be grouped into two families - the lysine-specific demethylase (LSD) family and Jumonji domain-containing (JmjC) family [221].”
BackgroundThe nexus of chromatin regulation and intermediary metabolism
Gut, P., & Verdin, E. (2013) · Nature · doi:10.1038/nature12752 · Cited by 421
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 395
“opment and several inhibitors of DNA methyltransferases, and histone deacetylases are approved by the Food and Drug Administration (FDA) for clinical use in cancers [31].”
BackgroundYTH Domain: A Family of N 6-Methyladenosine (m 6 A) Readers
Liao, S., Sun, H., & Xu, C. (2018) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.04.002 · Cited by 396
“In the epigenetic field, the structural information of known mediators or readers of histone acetyllysine and methyllysine has been used to guide the design and development of chemical probes [69].”
BackgroundThe epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
“specifically being tested for the treatment of AD, with most others having an approved indication in cancer treatment (Arrowsmith et al., 2012).”
BackgroundSelective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 376
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M. N., Hedlund, E. K., Rusch, M. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4630 · Cited by 379
Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.-Y., Zhao, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 358
Tschumperlin, D. J., Ligresti, G., Hilscher, M. B., & Shah, V. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93561 · Cited by 330
Lipids Reprogram Metabolism to Become a Major Carbon Source for Histone Acetylation
McDonnell, E., Crown, S. B., Fox, D. B., Kitir, B., Ilkayeva, O. R., Olsen, C. A., Grimsrud, P. A., & Hirschey, M. D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.012 · Cited by 351
“Targeting epigenetics and metabolism are aggressively being pursued as independent strategies to treat a variety of diseases (Arrowsmith et al., 2012).”
BackgroundLockwood, W. W., Zejnullahu, K., Bradner, J. E., & Varmus, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216363109 · Cited by 327
“This recognition step is critical in the regulation of gene expression, as the nuclear reader proteins recruit the necessary factors that initiate mRNA transcription and support mRNA elongation (2).”
BackgroundWD40 repeat domain proteins: a novel target class?
Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335
Self-citationChildren's Oncology Group's 2013 blueprint for research: Neuroblastoma
Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24433 · Cited by 332
“These genes include potentially druggable classes of enzymes and/or protein:protein interaction domains, and elucidating the biology of deregulated epigenesis in NBL may identify more specific therapeutic targets [55,56].”
BackgroundEpigenetic regulation by gut microbiota
Woo, V., & Alenghat, T. (2022) · Gut Microbes · doi:10.1080/19490976.2021.2022407 · Cited by 319
“the histone-DNA complexes (heterochromatin) denote inaccessible and silenced regions.(11) Epigenetic modifications that dynamically regulate chromatin accessibility include post-translational modification of histones and DNA methylation, which are controlled by the activity of opposing epigenetic modifying enzymes.”
BackgroundDrug Discovery Targeting Bromodomain-Containing Protein 4
Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01761 · Cited by 303
Inhibitors of Protein Methyltransferases and Demethylases
Kaniskan, H. Ü., Martini, M. L., & Jin, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 297
Readout of Epigenetic Modifications
Patel, D. J., & Wang, Z. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072711-165700 · Cited by 313
Polyamines and cancer: implications for chemotherapy and chemoprevention
Nowotarski, S. L., Woster, P. M., & Casero, R. A. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.3 · Cited by 305
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M., Shih, I.-M., Wang, T.-L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 290
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
Liu, F., Barsyte-Lovejoy, D., Li, F., Xiong, Y., Korboukh, V., Huang, X.-P., Allali-Hassani, A., Janzen, W. P., Roth, B. L., Frye, S. V., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401480r · Cited by 268
Self-citationBiology and mechanisms of action of the vitamin D hormone
Pike, J. W., & Christakos, S. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.07.001 · Cited by 247
Fiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N. (2014) · Leukemia · doi:10.1038/leu.2014.119 · Cited by 284
“Among the deregulated epigenetic mechanisms, in addition to DNA methylation and histone (H) de-acetylation, alterations in histone H3 lysine (K)-specific methylation are involved in promoting the aberrant gene expression or ‘transcriptome’ in AML cells, which includes the deregulated expression of oncogenes and tumor…”
BackgroundCatalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
Yu, W., Chory, E. J., Wernimont, A. K., Tempel, W., Scopton, A., Federation, A., Marineau, J. J., Qi, J., Barsyte-Lovejoy, D., Yi, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms2304 · Cited by 281
Self-citationQin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
Kurita, M., Holloway, T., García-Bea, A., Kozlenkov, A., Friedman, A. K., Moreno, J. L., Heshmati, M., Golden, S. A., Kennedy, P. J., Takahashi, N., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3181 · Cited by 285
Schmidt, M., Dekker, F. J., & Maarsingh, H. (2013) · Pharmacological Reviews · doi:10.1124/pr.110.003707 · Cited by 267
“4B), the reports place Epac not only into the context of epigenetic regulation of gene expression (Arrowsmith et al., 2012), but also in posttranscriptional modification of cytosolic proteins via (de)acetylation.”
BackgroundRan, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263
“Introduction Protein–protein interactions (PPIs) are potential drug targets for a broad range of therapeutic areas, such as oncology [1,2 ,3,4 ,5], immune-checkpoints for cancer immunotherapy [6], tropical infectious diseases [7 ], neurological disorders [8], heart failure [9] and inflammation”
BackgroundA cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1
Stuckey, J. I., Dickson, B. M., Cheng, N., Liu, Y., Norris, J. L., Cholensky, S. H., Tempel, W., Qin, S., Huber, K. G., Sagum, C., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2007 · Cited by 225
“Structure activity relationship (SAR) studies ultimately led to the synthesis of UNC3866 (2) (Fig.”
BackgroundSelf-citationAcetylation on histone H3 lysine 9 mediates a switch from transcription initiation to elongation
Gates, L. A., Shi, J., Rohira, A. D., Feng, Q., Zhu, B., Bedford, M. T., Sagum, C. A., Jung, S. Y., Qin, J., Tsai, M.-J., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.802074 · Cited by 249
“A variety of potential reader proteins containing either Bromo or YEATS domains, previously characterized to recognize acetylated lysine residues (33, 34), were detected by LC-MS (Fig.”
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gomez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 229
8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential
Song, Y., Xu, H., Chen, W., Zhan, P., & Liu, X. (2015) · MedChemComm · doi:10.1039/c4md00284a · Cited by 235
Designing Regenerative Biomaterial Therapies for the Clinic
Pashuck, E. T., & Stevens, M. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002717 · Cited by 240
Bromodomains: Structure, function and pharmacology of inhibition
Ferri, E., Petosa, C., & McKenna, C. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.005 · Cited by 229
Theodoulou, N. H., Bamborough, P., Bannister, A. J., Becher, I., Bit, R. A., Che, K. H., Chung, C.-W., Dittmann, A., Drewes, G., Drewry, D. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00256 · Cited by 235
Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM
Wong, A. S. L., Choi, G. C. G., Cui, C. H., Pregernig, G., Milani, P., Adam, M., Perli, S. D., Kazer, S. W., Gaillard, A., Hermann, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517883113 · Cited by 242
“Using the Drug–Gene Interaction database (DGIdb) (19) and recent literature (20, 21), we confirmed that at least 26 of the 50 genes in our library are known drug targets.”
BackgroundDNA methylation and childhood asthma in the inner city
Yang, I. V., Pedersen, B. S., Liu, A., O'Connor, G. T., Teach, S. J., Kattan, M., Misiak, R. T., Gruchalla, R., Steinbach, S. F., Szefler, S. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.025 · Cited by 226
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Regulatory Enhancer–Core-Promoter Communication via Transcription Factors and Cofactors
Zabidi, M. A., & Stark, A. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.10.003 · Cited by 228
Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?
Harrison, I. F., & Dexter, D. T. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.010 · Cited by 227
“…epigenome (literally meaning ‘above the genome’): the combination of DNA and histone post-translational modifications and related interacting proteins that together package the genome and help define the transcriptional programme of a given cell (Bernstein et al., 2007; Arrowsmith et al., 2012).”
BackgroundInhibition of demethylases by GSK-J1/J4
Heinemann, B., Nielsen, J. M., Hudlebusch, H. R., Lees, M. J., Larsen, D. V., Boesen, T., Labelle, M., Gerlach, L.-O., Birk, P., & Helin, K. (2014) · Nature · doi:10.1038/nature13688 · Cited by 228
Xu, B., On, D. M., Ma, A., Parton, T., Konze, K. D., Pattenden, S. G., Allison, D. F., Cai, L., Rockowitz, S., Liu, S., et al. (2015) · Blood · doi:10.1182/blood-2014-06-581082 · Cited by 227
“As the regulatory factors involved in the installation, removal, or recognition of histone modification (often termed as epigenetic “writers,” “erasers,” and “readers”(1)) are increasingly considered to be “druggable,”(5-7) development of epigenetic modulators holds promise for novel therapeutic interventions.(7,8) Po…”
BackgroundThe EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2306 · Cited by 224
Self-citationDNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy
Zhang, J., Yang, C., Wu, C., Cui, W., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12082123 · Cited by 208
“At present, epigenetics spans many research fields, such as oncology and immunology [2].”
BackgroundEpigenetic treatment of solid tumours: a review of clinical trials
Nervi, C., De Marinis, E., & Codacci-Pisanelli, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0157-2 · Cited by 213
“The possibility of drug development in this field has recently been reviewed [22, 24, 30, 31].”
BackgroundHistone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Neganova, M. E., Klochkov, S. G., Aleksandrova, Y. R., & Aliev, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.015 · Cited by 197
Methyltransferases: Functions and Applications
Abdelraheem, E., Thair, B., Varela, R. F., Jockmann, E., Popadić, D., Hailes, H. C., Ward, J. M., Iribarren, A. M., Lewkowicz, E. S., Andexer, J. N., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200212 · Cited by 198
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
McLure, K. G., Gesner, E. M., Tsujikawa, L., Kharenko, O. A., Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083190 · Cited by 198
The bromodomain: From epigenome reader to druggable target
Sanchez, R., Meslamani, J., & Zhou, M.-M. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.011 · Cited by 197
Histone deacetylases: structural determinants of inhibitor selectivity
Micelli, C., & Rastelli, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.007 · Cited by 192
Sundar, I. K., Yao, H., & Rahman, I. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4863 · Cited by 193
“Histone modifications are regulated by specific chromatin modification enzymes, which have a residue-specific role in regulating gene expression with respect to histone modifications (9, 19, 68, 127).”
BackgroundEnhancer of zeste homolog 2 (EZH2) inhibitors
Gulati, N., Béguelin, W., & Giulino-Roth, L. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 193
Mechanisms of human histone and nucleic acid demethylases
Walport, L. J., Hopkinson, R. J., & Schofield, C. J. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.09.015 · Cited by 193
Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice
Zhang, L., Liu, C., Wu, J., Tao, J.-J., Sui, X.-L., Yao, Z.-G., Xu, Y.-F., Huang, L., Zhu, H., Sheng, S.-L., et al. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140066 · Cited by 192
“Over the past decade, lots of studies in vitro and vivo have identified many compounds of therapeutic interest [1, 2].”
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
Romero, F. A., Taylor, A. M., Crawford, T. D., Tsui, V., Côté, A., & Magnuson, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01514 · Cited by 188
vel Szic, K. S., Declerck, K., Vidaković, M., & Vanden Berghe, W. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0068-2 · Cited by 192
“To reverse such subtle changes, several nutrients and bioactive food compounds may be preferred over toxic antineoplastic epigenetic drugs [91,121,142,143,321-327].”
BackgroundProtein arginine methylation of non-histone proteins and its role in diseases
Wei, H., Mundade, R., Lange, K., & Lu, T. (2014) · Cell Cycle · doi:10.4161/cc.27353 · Cited by 190
“Also, an inhibitor named compound 2 was reported to be able to inhibit co-activator-associated PRMT1 with an IC 50 of 30 nM.(77) Recently, 2 potent and selective inhibitors of PRMT4 were reported.”
BackgroundFiskus, W., Sharma, S., Qi, J., Valenta, J. A., Schaub, L. J., Shah, B., Peth, K., Portier, B. P., Rodriguez, M., Devaraj, S. G. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0770 · Cited by 190
“The resulting histone states or "marks" are recognized by the "reader" proteins, which assemble a complex of coregulatory proteins at the enhancers or promoters that initiate and regulate gene transcription (2, 3).”
BackgroundUnusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718823114 · Cited by 190
( R )-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells
Barsyte-Lovejoy, D., Li, F., Oudhoff, M. J., Tatlock, J. H., Dong, A., Zeng, H., Wu, H., Freeman, S. A., Schapira, M., Senisterra, G. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407358111 · Cited by 185
“Methyltransferase activity of SETD7(1-366) was assayed using a scintillation proximity assay monitoring the incorporation of the tritium-labeled methyl group of (3)H-SAM into a peptide substrate corresponding to histone H3 residues 1–25 at 2 μM SAM and 2 μM H3(1–25) and 2 nM enzyme (Fig.”
BackgroundMethodSelf-citationTudor: a versatile family of histone methylation ‘readers’
Lu, R., & Wang, G. G. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.08.002 · Cited by 181
“Similar compounds could be developed to target other epigenetic readers that are disease associated [5,6,90,91].”
Driver mutations of cancer epigenomes
Roy, D. M., Walsh, L. A., & Chan, T. A. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 186
“HDACi, DNMT inhibitors) (Table 1) (Arrowsmith et al., 2012; Foulks et al., 2012; Helin and Dhanak, 2013; New et al., 2012; Plass et al., 2013).”
Hewings, D. S., Rooney, T. P. C., Jennings, L. E., Hay, D. A., Schofield, C. J., Brennan, P. E., Knapp, S., & Conway, S. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300915b · Cited by 181
Pioneer of prostate cancer: past, present and the future of FOXA1
Teng, M., Zhou, S., Cai, C., Lupien, M., & He, H. H. (2021) · Protein & Cell · doi:10.1007/s13238-020-00786-8 · Cited by 175
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions
Hoeksema, M. A., Gijbels, M. J., Van den Bossche, J., van der Velden, S., Sijm, A., Neele, A. E., Seijkens, T., Stöger, J. L., Meiler, S., Boshuizen, M. C., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404170 · Cited by 179
“Epigenetic enzymes regulate histone tail modifications, such as acetylation and methylation that alter chromatin accessibility and thereby control transcriptional responses (Arrowsmith et al , 2012).”
de Groote, M. L., Verschure, P. J., & Rots, M. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks863 · Cited by 180
San José-Enériz, E., Agirre, X., Rabal, O., Vilas-Zornoza, A., Sanchez-Arias, J. A., Miranda, E., Ugarte, A., Roa, S., Paiva, B., Estella-Hermoso de Mendoza, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15424 · Cited by 171
Genome-wide localization of small molecules
Anders, L., Guenther, M. G., Qi, J., Fan, Z. P., Marineau, J. J., Rahl, P. B., Lovén, J., Sigova, A. A., Smith, W. B., Lee, T. I., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2776 · Cited by 179
Marek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
“Most HDAC inhibitors that are currently approved for use in humans, or are in clinical trials are, at best, moderately selective for an HDAC class [48] and not for one particular enzyme.”
BackgroundPolycomb-dependent epigenetic landscape in adult T-cell leukemia
Fujikawa, D., Nakagawa, S., Hori, M., Kurokawa, N., Soejima, A., Nakano, K., Yamochi, T., Nakashima, M., Kobayashi, S., Tanaka, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662593 · Cited by 173
“Importantly, epigenomic states that maintain and perpetuate tumor characteristics are potentially reversible cellular states that may be unlocked by epigenetic therapy, which is more clinically manageable than targeting irreversible genomic alterations.(21) In this study, we performed integrative analyses of the epige…”
Wei, L., Chiu, D. K.-C., Tsang, F. H.-C., Law, C.-T., Cheng, C. L.-H., Au, S. L.-K., Lee, J. M.-F., Wong, C. C.-L., Ng, I. O.-L., & Wong, C.-M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.015 · Cited by 163
“Unlike genetic alterations, 66 these epigenetic changes are often reversible, which makes epigenetic therapy an attractive 67 direction for anti-cancer drug development [6].”
BackgroundPotent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
He, S., Dong, G., Li, Y., Wu, S., Wang, W., & Sheng, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201915896 · Cited by 167
The emerging and diverse roles of sirtuins in cancer: a clinical perspective
Chen, W., Yuan, H., & Su, L. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s37750 · Cited by 162
“122 In addition, a specific SIRT1 inhibitor EX-527 is in a Phase II clinical trial for treating Huntington’s disease, 174 although its effect on cancer remains unclear.”
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 159
“2, 3, 31–33, and Figure 1).”
Epigenetic Regulatory Mechanisms Induced by Resveratrol
Fernandes, G., Silva, G., Pavan, A., Chiba, D., Chin, C., & Dos Santos, J. (2017) · Nutrients · doi:10.3390/nu9111201 · Cited by 161
“Classes I, IIa, IIb and IV are dependent on divalent metal ions for their catalytic activity, whereas the sirtuins are NAD+-dependent enzymes and are structurally and biochemically unrelated to the other HDAC classes [78].”
Background
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.